Insulin therapy for type 2 diabetes: premixed or basal-prandial?

Diabetes and Metabolism

Volumn 33, Issue 4, 2007, Pages 316-320

  Halbron, M ^a   Jacqueminet, S ^a   Sachon, C ^a   Bosquet, F ^a   Hartemann Heurtier, A ^a   Grimaldi, A ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Fasting hyperglycaemia; HbA1c; Insulin therapy; postprandial hyperglycaemia; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; DIABETES CONTROL; DIET RESTRICTION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; SIDE EFFECT; WEIGHT GAIN; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 34548691653     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2007.01.005     Document Type: Note

References (23)

1. Riddle M.C. Evening insulin strategy. Diabetes Care 13 (1990) 676-686
2. Yki-Järvinen H., Kauppila M., Kujansuu E., et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 327 (1992) 1426-1433
3. Yki-Järvinen H., Ryysy L., Nikkilä K., Tulokas T., Vanamo R., and Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann. Intern. Med. 130 (1999) 389-396
4. Riddle M.C., Rosenstock J., Gerich J., and on behalf of the Insulin Glargine 4002 Study Investigators. The treat-to-target trial. Diabetes Care 26 (2003) 3080-3086
5. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
6. Shichiri M., Kishikawa H., Ohkubo Y., and Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 Suppl. 2 (2000) B21-B29
7. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients. Diabetes Care 26 (2003) 881-885
8. 1c. Diabetes Care 23 (2000) 1236-1241
9. Wright A., Burden A.C., Paisey R.B., Cull C.A., Holmazn R.R., and for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336
10. Alvarsson M., Sundkvist G., Lager I., et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26 (2003) 2231-2237
11. Yki-Järvinen H., Kauppinen-Mäkelin R., Tikkainen M., et al. Insulin glargine or NPH combined with metformin in type 1 diabets: the KANMET study. Diabetologia 49 (2006) 442-451
12. Yki-Järvinen H., Dressler A., Ziemen M., and the HOE 901/3002 Study Group. Less nocturnal hypoglycaemia and better postdinner glucose control with bedtime insulin Glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23 (2000) 1130-1136
13. Fritsche A., Schweiltzer A., Häring H.H., and and the 1001 Study Group. Glimepiride combined with morning insulin glargine bedtime neutral Protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized controlled trial. Ann. Intern. Med. 138 (2003) 952-959
14. Hermansen K., Davies M., Derezinski T., Martinez Ravn G., Clauson P., Home P., and on behalf of the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin Detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïves people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
15. Chow C.C., Tsang L.W.W., Sorensen J.P., and Cockram C.S. Comparison of insulin with or without continuation of oral hypoglycaemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 18 (1995) 307-314
16. Yki-Järvinen H. Comparison of insulin regimens for patients with type 2 diabetes. Curr Opin Endocrinol Diabetes 7 (2000) 175-183
17. Malone J.K., Bai S., Campaigne B.N., Reviriego J., and Augendre-Ferrante B. Twice-daily premixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet. Med. 22 (2005) 1-8
18. Janka H.U., Plewe G., Riddle M.C., Kliebe-Frisch C., Schweitzer M.A., and Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
19. Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes?. Diabetes Care 28 (2005) 260-265
20. Garber A.J., Wahlen J., Wahl T., et al. Attainment of glycaemic goals in type 2 diabetes with once, twice of thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes. Metab. 8 (2006) 58-66
21. Monnier L., Benichou M., Charra-Ebrard S., Boegner C., and Colette C. Revue du rationnel des stratégies pharmacologiques dans le diabète de type 2 : des preuves aux nouvelles perspectives. Diabetes Metab. 31 (2005) 101-109
22. Riddle M.C. Timely initiation of basal insulin. Am. J. Med. 116 Suppl.3A (2004) 35-95
23. Abraira C., Henderson W.G., Colwell J.A., et al., for the VA CSDM Group. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. Diabetes Care 21 (1998) 574-579